NCT01933919View on ClinicalTrials.gov

A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 14, 2013

Primary Completion Date

June 18, 2015

Study Completion Date

July 1, 2016

Conditions
Obsessive Compulsive Disorder
Interventions
DRUG

Fluvoxamine maleate

Film-coated tablet containing 25 mg of fluvoxamine maleate

DRUG

Placebo

Placebo tablet matching to fluvoxamine maleate

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
collaborator

Meiji Seika Pharma Co., Ltd.

INDUSTRY

lead

AbbVie

INDUSTRY